© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 13, 2021
Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.
May 12, 2021
The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with Crohn’s disease was a predictor of disease severity.
May 11, 2021
A new study compares patients self-reported outcomes after depot or daily sublingual buprenorphine treatment, including satisfaction and burden rates.
The majority of adverse effects reported were considered mild.
A new study presented at ASGCT found that patients with indications of hemostatic efficacy experienced few adverse effects with gene therapy treatment BAY 2599023.
Noah Rindos, MD, Talks Fibroids, Adenomyosis and Pregnancy
Kausik Ray, MD: A Risk-Based Look at LDL Cholesterol Lowering
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy